Literature DB >> 14526374

Advances in Duchenne muscular dystrophy gene therapy.

Judith C T van Deutekom1, Gert-Jan B van Ommen.   

Abstract

Since the initial characterization of the genetic defect for Duchenne muscular dystrophy, much effort has been expended in attempts to develop a therapy for this devastating childhood disease. Gene therapy was the obvious answer but, initially, the dystrophin gene and its product seemed too large and complex for this approach. However, our increasing knowledge of the organization of the gene and the role of dystrophin in muscle function has indicated ways to manipulate them both. Gene therapy for Duchenne muscular dystrophy now seems to be in reach.

Entities:  

Mesh:

Year:  2003        PMID: 14526374     DOI: 10.1038/nrg1180

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  67 in total

Review 1.  Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment.

Authors:  Kristen J Nowak; Kay E Davies
Journal:  EMBO Rep       Date:  2004-09       Impact factor: 8.807

Review 2.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

3.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.

Authors:  Chengzu Long; John R McAnally; John M Shelton; Alex A Mireault; Rhonda Bassel-Duby; Eric N Olson
Journal:  Science       Date:  2014-08-14       Impact factor: 47.728

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

5.  Quantifying myofiber integrity using diffusion MRI and random permeable barrier modeling in skeletal muscle growth and Duchenne muscular dystrophy model in mice.

Authors:  Kerryanne V Winters; Olivier Reynaud; Dmitry S Novikov; Els Fieremans; Sungheon Gene Kim
Journal:  Magn Reson Med       Date:  2018-03-25       Impact factor: 4.668

Review 6.  Gene therapy in large animal models of muscular dystrophy.

Authors:  Zejing Wang; Jeffrey S Chamberlain; Stephen J Tapscott; Rainer Storb
Journal:  ILAR J       Date:  2009

7.  Assessment of the feasibility of exon 45-55 multiexon skipping for Duchenne muscular dystrophy.

Authors:  Laura van Vliet; Christa L de Winter; Judith C T van Deutekom; Gert-Jan B van Ommen; Annemieke Aartsma-Rus
Journal:  BMC Med Genet       Date:  2008-12-01       Impact factor: 2.103

8.  Gene diagnosis for nine Chinese patients with DMD/BMD by multiplex ligation-dependent probe amplification and prenatal diagnosis for one of them.

Authors:  Yupeng Wu; Gengxin Yin; Keqin Fu; De Wu; Qian Zhai; Huarong Du; Zhongjun Huang; Yuhua Niu
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

9.  Cooperation of Mtmr8 with PI3K regulates actin filament modeling and muscle development in zebrafish.

Authors:  Jie Mei; Zhi Li; Jian-Fang Gui
Journal:  PLoS One       Date:  2009-03-26       Impact factor: 3.240

10.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.